Ken Griffin Arcus Biosciences, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,700 shares of RCUS stock, worth $230,790. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,700

Previous 2,800 460.71%

Holding current value

$230,790

Previous $42,000 471.43%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$13.69 - $18.01 $2.04 Million - $2.69 Million	-149,292 Reduced 31.96%	317,871 $4.86 Million
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $1.64 Million - $2.07 Million	112,242 Added 31.62%	467,163 $7.11 Million
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $1.17 Million - $1.59 Million	78,997 Added 28.63%	354,921 $6.7 Million
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $133,265 - $194,788	-9,923 Reduced 3.47%	275,924 $5.27 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $7.93 Million - $10.6 Million	-449,782 Reduced 61.14%	285,847 $5.13 Million
Q2 2023 Aug 14, 2023	SELL	$16.97 - $22.03 $17.5 Million - $22.7 Million	-1,030,379 Reduced 58.35%	735,629 $14.9 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $17.9 Million - $26 Million	1,122,779 Added 174.55%	1,766,008 $32.2 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $12.1 Million - $22 Million	616,739 Added 2328.2%	643,229 $13.3 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $589,879 - $763,567	-25,393 Reduced 48.94%	26,490 $693,000
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $550,929 - $1.21 Million	31,975 Added 160.61%	51,883 $1.32 Million
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $4.1 Million - $5.94 Million	-141,902 Reduced 87.7%	19,908 $628,000
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $4.2 Million - $6.48 Million	133,722 Added 476.08%	161,810 $6.55 Million
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $378,662 - $529,818	-14,061 Reduced 33.36%	28,088 $979,000
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $250,318 - $393,577	-11,003 Reduced 20.7%	42,149 $1.16 Million
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $1.11 Million - $1.75 Million	-42,361 Reduced 44.35%	53,152 $1.49 Million
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $348,007 - $662,441	-20,471 Reduced 17.65%	95,513 $2.48 Million
Q3 2020 Nov 16, 2020	SELL	$17.14 - $25.47 $4.35 Million - $6.47 Million	-254,042 Reduced 68.66%	115,984 $1.99 Million
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $4.73 Million - $12.4 Million	338,436 Added 1071.34%	370,026 $9.16 Million
Q1 2020 May 15, 2020	SELL	$8.78 - $19.28 $223,837 - $491,524	-25,494 Reduced 44.66%	31,590 $439,000
Q4 2019 Feb 14, 2020	BUY	$7.33 - $10.79 $14,967 - $22,033	2,042 Added 3.71%	57,084 $577,000
Q3 2019 Nov 14, 2019	SELL	$6.44 - $10.18 $93,347 - $147,559	-14,495 Reduced 20.85%	55,042 $500,000
Q2 2019 Aug 14, 2019	BUY	$7.29 - $13.38 $379,211 - $696,000	52,018 Added 296.92%	69,537 $553,000
Q1 2019 May 15, 2019	BUY	$8.95 - $12.49 $156,795 - $218,812	17,519 New	17,519 $0

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.7M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account